Teva announces new generic drug for treating bacterial infections

IRVINE, Calif. Teva announced today the availability of its new drug ceftriaxone for injection.

Ceftriaxone for injection is available in 250 mg/vial, 500 mg/vial, 1 gm/vial and 2 gm/vial, in single dose glass vials, and 10 gm/vial in multiple-dose glass vials. The drug, whose brand name is Rocephin, is used to treat or prevent infections that are proven or strongly suspected to by caused by bacteria.

“Teva Health Systems is committed to providing high-quality, cost-effective pharmaceuticals to our customers and patients,” stated Jonathan Zalk, marketing director. “We are excited to offer Ceftriaxone for injection to meet their needs.”